MDMA is primarily being studied as a treatment for post-traumatic stress disorder (PTSD), and it has also shown early promise for eating disorder symptoms and social anxiety. No country has approved MDMA as a medicine yet. In the United States, the FDA rejected an application to approve MDMA-assisted therapy for PTSD in August 2024, citing concerns about the strength of the evidence. But the compound remains one of the most closely watched experimental treatments in psychiatry, and clinical trials continue.
PTSD Is the Primary Target
The vast majority of clinical research on therapeutic MDMA has focused on PTSD, particularly severe cases that haven’t responded well to existing treatments. The FDA designated MDMA-assisted therapy as a Breakthrough Therapy for PTSD in 2017, a label reserved for treatments that may offer substantial improvement over what’s currently available. That designation fast-tracked the research process and led to two large Phase 3 clinical trials.
The idea isn’t that MDMA treats PTSD on its own. It’s used alongside a structured course of psychotherapy. The treatment protocol involves three types of sessions: preparatory sessions, MDMA sessions, and integration sessions. Before the first dose, patients complete three 90-minute preparatory sessions to build trust with their therapists and set goals. Then they undergo two to three MDMA sessions, each followed by three 90-minute integration sessions where they process what came up. A full course of treatment involves roughly 12 to 15 therapy sessions total, with MDMA present in only two or three of them.
The logic behind this approach comes down to how MDMA affects the brain. The compound floods the brain with serotonin by both blocking its reabsorption and reversing the transporters that normally pull it back into nerve cells. This surge of serotonin, along with effects on areas like the amygdala (which regulates fear and emotional reactivity), appears to create a window where people can revisit traumatic memories without the usual overwhelming fear response. That window gives therapists a chance to do deeper work than talk therapy alone typically allows.
Why the FDA Rejected Approval in 2024
Despite encouraging trial results, the FDA formally rejected MDMA-assisted therapy for PTSD on August 9, 2024. The agency issued a Complete Response Letter to Lykos Therapeutics, the company that submitted the application, outlining several concerns. The FDA questioned whether the clinical trials adequately proved efficacy, raised issues about the difficulty of combining a drug treatment with psychotherapy in a standardized way, and pointed to potential bias in the trial design.
The FDA’s response asked Lykos to conduct an additional Phase 3 clinical trial before resubmitting, a significant and expensive requirement. MDMA remains a Schedule I substance under federal law, classified as having no accepted medical use since 1985. However, the FDA did authorize Expanded Access (sometimes called “compassionate use”) starting in 2022, which allows some patients to receive MDMA-assisted therapy in FDA-regulated settings outside of clinical trials.
Eating Disorder Symptoms
Eating disorders and PTSD frequently overlap, and researchers have begun exploring whether MDMA-assisted therapy might help with both simultaneously. In a double-blind, placebo-controlled trial of 90 people with severe PTSD, researchers also measured eating disorder symptoms using a standardized screening tool. At baseline, about 15% of participants scored in the clinical range for disordered eating, and nearly a third scored in a high-risk range, even though none had active purging behaviors or dangerously low weight.
The results were notable. Participants who received MDMA-assisted therapy showed significantly greater reductions in eating disorder symptoms compared to those who received therapy with a placebo. The effect was particularly strong among women with elevated scores at the start of the study. This research is still early, and the eating disorder findings were exploratory rather than the primary focus of the trial, but they suggest MDMA-assisted therapy may address psychological patterns that fuel disordered eating, especially when trauma is involved.
Social Anxiety
Small studies have also investigated MDMA-assisted therapy for social anxiety, including in autistic adults. The rationale is similar to the PTSD work: MDMA’s effects on serotonin and emotional processing may temporarily reduce the fear and defensiveness that make social situations distressing, giving therapists an opening to help patients build new patterns. This research is in much earlier stages than the PTSD trials, and no large controlled studies have been completed yet.
Side Effects in Clinical Settings
MDMA-assisted therapy is not without physical side effects, even in controlled medical environments. Data pooled from the two major Phase 3 PTSD trials paint a clear picture of what participants experienced during and after dosing sessions.
The most common side effects were jaw clenching and tightness (reported by about 58% of MDMA participants versus 15% on placebo), headache (72% versus 58%), decreased appetite (43% versus 11%), insomnia (39% versus 30%), nausea (38% versus 17%), and excessive sweating (28% versus 4%). Many participants also reported feeling cold or hot, fatigue, dizziness, muscle tightness, and restlessness.
Cardiovascular effects were more concerning. Blood pressure rose by an average of 17 points systolic and 7 points diastolic, and heart rate increased by an average of 23 beats per minute. About 68% of MDMA-treated participants had blood pressure readings at or above 140/90 at some point during sessions, compared to 22% on placebo. Roughly 6% reached severely elevated systolic readings above 180. The compound also affected temperature regulation and fluid balance, with higher rates of sweating, chills, and shifts in body temperature perception.
These effects generally occurred during the dosing sessions themselves and were managed by the clinical teams present. But they underscore why this treatment is designed for supervised medical settings rather than self-administration, and why cardiovascular health is a screening consideration for potential patients.